Immunomedics

Immunomedics is a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer.

Immunomedics
Traded asNASDAQ: IMMU
Russell 2000 Component
Websitehttps://immunomedics.com

Immunomedics was founded in July 1982 by David M. Goldenberg. Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019.[1] Dr. Behzad Aghazadeh was named Executive Chairman of the Board of Directors after Pehl's departure.[2]

Pipeline
  • Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.
  • Sacituzumab govitecan (IMMU-132) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease[3]
  • Labetuzumab govitecan (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.
  • Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.
  • Milatuzumab is an anti-CD74 monoclonal antibody for autoimmune diseases.
  • IMMU-114 is an anti-HLA-DR for hematological cancers.[4]

References
  1. "Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach". endpts.com. Retrieved 2019-06-21.
  2. "Iannone walks out on troubled Immunomedics a year after taking CMO job". fiercebiotech.com. Retrieved 2019-06-21.
  3. "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments". FDA. 2020-04-22. Retrieved 2020-04-24.
  4. "Corporate overview" (PDF). www.immunomedics.com. February 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.